Triple-negative breast cancer (TNBC), characterized by the lack of estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor-2 (HER2) overexpression or gene amplification, represents approximately 15% of all breast tumors1. Here, ERBB2 is linked to triple-negative breast carcinoma.